Ágoston Emese Irma, Baranyai Zsolt, Dede Kristóf, Bodoky György, Kulka Janina, Bursics Attila, Harsányi László, Szász A Marcell
I. Sebészeti Klinika, Semmelweis Egyetem, Általános Orvostudományi Kar Budapest, Üllői út 78., 1082.
Orv Hetil. 2015 Sep 6;156(36):1460-71. doi: 10.1556/650.2015.30218.
Besides clinicopathological parameters, molecular markers can be very important, and further characterize colorectal carcinomas into chromosomally unstable, microsatellite instable and "CqG-island methylator phenotype" groups.
To study the frequency of microsatellite instability using immunohistochemical evaluation of MLH1, MSH2, MSH6 and PMS2 proteins in colorectal carcinoma.
122 colorectal carcinomas as well as in 69 paired liver metastases were evaluated. Additionally, prognostic and predictive potential of mismatch repair status was tested.
Microsatellite instable phenotype was identified in 11.5% (14/122) of the tumours. There were no differences regarding staining intensity of tumour regions. Mismatch repair status was discordant in primaries vs. metastases in 20.2%. There was no difference in progression free- and overall survival according to mismatch repair status. The mismatch repair status was not predictive for survival within systemic therapy regimen groups.
The subgroups of colorectal carcinomas could be evaluated in a larger and homogenised patient cohort to predict prognosis and response to therapy.
除临床病理参数外，分子标志物可能非常重要，它可进一步将结直肠癌分为染色体不稳定型、微卫星不稳定型和“CqG岛甲基化表型”组。
通过免疫组化评估结直肠癌中MLH1、MSH2、MSH6和PMS2蛋白来研究微卫星不稳定性的频率。
对122例结直肠癌以及69例配对的肝转移灶进行评估。此外，还测试了错配修复状态的预后和预测潜力。
11.5%（14/122）的肿瘤表现为微卫星不稳定型。肿瘤区域的染色强度无差异。20.2%的原发灶与转移灶的错配修复状态不一致。根据错配修复状态，无进展生存期和总生存期无差异。错配修复状态对全身治疗方案组内的生存无预测作用。
可在更大且同质化的患者队列中评估结直肠癌亚组，以预测预后和治疗反应。
